Tirzepatide Research: How It Works and What Trials Found
Why was Tirzepatide made, and what came next?
A research team first described Tirzepatide in 2018. Their goal was one medicine that could carry both gut-hormone messages and lower blood sugar. Phase 1, the first small testing stage in people, also showed weight loss.
Large Phase 3 studies came next. These were the final large tests before approval. The type 2 diabetes studies ran in 2020–2021. The main obesity result came in 2022, followed by approvals in 2022 and 2023.
From 2024 through 2026, researchers asked four more questions. They studied heart failure, sleep apnea, fatty liver, and kidney health. Here you can see what was shown and what remains unsure.
Tirzepatide mechanism of action: how do the two gut hormones help?
The first Tirzepatide paper appeared in 2018. Repeat doses cut food intake and weight more in mice than the other drug did. That comparison drug was based on GLP-1, one gut hormone. An early Phase 1 test, the first small study in people, followed 142 adults. It found a weekly pattern along with lower fasting sugar and weight than placebo [1].
A 2020 test used living cells outside the body. It compared the GLP-1 message with the second gut-hormone message. Tirzepatide sent the GLP-1 message differently from natural GLP-1. In pancreas cells, the drug produced a strong insulin reply [2]. Researchers think this may help explain what later happened in people.
The two hormone messages cause several changes. More insulin enters your blood whenever sugar is high, while the liver releases less sugar. Food stays in your stomach longer, which may reduce your hunger [1][10]. A 2023 review explains these drugs in more detail [10].
A lab makes Tirzepatide as a straight 39-amino-acid chain. A fatty part on the medicine helps it attach to albumin. That blood protein slows the drug’s exit. Its 5-day half-life means about half a dose remains after five days [1].
Tirzepatide vs semaglutide: what did direct trials show?
Two trials compared Tirzepatide directly with semaglutide. The type 2 diabetes trial measured blood sugar. The obesity trial measured weight. For you, the limit matters: these findings apply only to the people and doses tested.
SURPASS-2: type 2 diabetes over 40 weeks: This phase 3 study, a final large test before approval, followed 1,879 adults. The doses were 5/10/15 mg, meaning five, ten, and fifteen milligrams. The blood test of average sugar fell by 2.01/2.24/2.30 points in that same order. Semaglutide 1 mg lowered it by 1.86 points. Tirzepatide also led to 1.9, 3.6, and 5.5 kg more weight loss in that dose order. Most gut problems were mild or medium, though they were common [3].
SURMOUNT-5: obesity without type 2 diabetes over 72 weeks: This later large study followed 751 adults. At the highest dose each person could tolerate, average weight fell by 20.2% with Tirzepatide and 13.7% with semaglutide. More people taking Tirzepatide reached each weight mark. The paper wrote those marks as 10/15/20/25%, meaning ten, fifteen, twenty, and twenty-five percent. Their waist size also fell more [5].
Researchers put nine trials together in one review against dulaglutide. Tirzepatide led to larger changes in both sugar and weight; however side effects made about 32% more people stop [26]. A second review found that more people reached a three-month blood sugar result below 7.0%. The trial findings agreed closely, with 0% of the difference tied to variation between them. The gain was smaller after many years of diabetes with known heart or blood-vessel disease [20].
What did Tirzepatide studies find for the heart, sleep, liver, and kidneys?
Heart failure, SUMMIT, 2025: The study followed 731 adults who had obesity; their hearts squeezed well but didn’t fill well. The main 2025 report found a benefit for this form of heart failure [9]. A second 2025 report compared Tirzepatide with placebo after 52 weeks. Researchers saw a small drop of 5 millimetres of mercury in the top blood-pressure number. The 95% likely range was a fall of 3 to 7 millimetres of mercury. Blood volume and blood signs of swelling and heart strain also fell. Protein in urine fell 25.0% after 24 weeks. These findings suggest less strain on the heart and kidneys, but they don’t prove every effect [9].
Sleep apnea, SURMOUNT-OSA, 2024–2025: Two 52-week studies enrolled adults who had obesity plus sleep apnea rated moderate or severe. Tirzepatide reduced the hourly count of slow or stopped breaths more than placebo [11]. Improvement showed by Week 4, and a clear gap from placebo appeared by Week 20 [12]. Greater weight loss went with greater breathing gains. People also said they slept better and managed daytime life better. The EQ-5D-5L survey asked about everyday health, while SF-36 asked about day-to-day health. Both scores improved [11].
Fatty liver, SYNERGY-NASH, 2024: The 2024 report followed adults with a swollen, fatty liver and moderate-to-severe scarring. They took Tirzepatide 5, 10, or 15 mg once a week. Active liver disease cleared at a higher rate than placebo, without worse scarring [14].
Kidneys, SURPASS-CVOT, 2026: This early finding came from a heart study of 13,165 adults with type 2 diabetes and artery disease. The study followed people for a middle time of 4.0 years. Kidney filtering fell more slowly with Tirzepatide. The paper gave a 95% range for that finding. Among people at high kidney risk, fewer reached the combined measure of serious kidney trouble. A second 95% range showed how much that estimate could vary [13].
Tirzepatide results: how much did blood sugar and weight change?
SURPASS-2 gives the clearest sugar comparison. At 15 mg, the test covering about three months of sugar fell by 2.30 percentage points over 40 weeks. Semaglutide 1 mg lowered it by 1.86 points in the same 1,879 adults [3].
A Chinese study tested early diabetes. At 5, 10, and 15 mg, the sugar test fell by 2.04%, 1.93%, and 2.02% after 40 weeks. Weight fell by 5.0, 5.1, and 8.7 kg in that dose order [27].
SURMOUNT-1 had the largest weight result here. At 15 mg, the average drop was 20.9%, against 3.1% with placebo. The study ran 72 weeks and included 2,539 people [4].
SURMOUNT-5 compared the drugs directly. After 72 weeks, the averages were 20.2% with Tirzepatide and 13.7% with semaglutide among 751 adults [5].
A StatPearls review confirms the May 2022 FDA approval for type 2 diabetes. It says Tirzepatide copies GLP-1, a gut hormone, plus a second hormone, and it covers safety [7].
What did Tirzepatide studies add from 2024 to 2026?
Kidney update, 2026: Tirzepatide caused fewer major kidney problems than dulaglutide. Fewer low-to-medium-risk people developed high protein in urine. Kidney filtering also fell more slowly in the high-risk group [13]. A 95% range showed the estimate’s uncertainty. For you, this suggests an early kidney benefit.
Tirzepatide against dulaglutide, 2026: A review favored Tirzepatide for the sugar test and weight. Gut trouble made more people leave treatment. More people reached a sugar result below 7.0%. The trials agreed closely, with measured variation at 0%. The gain was smaller after years of diabetes with known heart or blood-vessel disease [20].
Drugs that can add weight, 2026: About one-fifth of SURMOUNT members used such medicines. Against placebo, weight fell from 13.3% to 21.3% by week 72. For you, the amount must be read with the dose and trial. It stayed close to results in people not split by those drugs [28].
Chinese diabetes study, 2026: Adults with early type 2 diabetes used Tirzepatide alone. For the five, ten, and fifteen milligram doses, sugar-test changes were −2.04/−1.93/−2.02%, in that order. Each week 40 result was too clear to explain by chance alone [27].